¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Simons disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • sexually transmitted disease
    ¼º¸Å°³º´, ¼ºº´
  • sickle cell disease
    ³´ÀûÇ÷±¸º´
  • Sandhoff¡¯s disease
    ÀÜÆ®È£ÇÁº´
  • silo filler¡¯s disease
    »çÀϷγóºÎº´, ¸¶ÃÊÀúÀå°í³óºÎº´
  • Simmonds¡¯ disease
    ½Ã¸ÕÁ
  • sleeping disease
    ¼ö¸éº´
  • Takayasu¡¯s disease
    ´ÙÄ«¾ß½ºº´
  • Tangier disease
    źÁö¿¡¸£º´
  • Unverricht¡¯s disease
    ¿îº£¸®È÷Æ®º´
  • upper motor neuron disease
    À§¿îµ¿½Å°æ¼¼Æ÷º´, »óÀ§¿îµ¿½Å°æ¿øº´
  • upper respiratory disease
    »ó±âµµº´
  • vascular disease
    Ç÷°üº´
  • venereal disease
    ¼ºº´
  • venereal disease control
    ¼ºº´°ü¸®
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç, VDRL°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • hemolytic disease
    ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of fetus/newborn
    žÆ/½Å»ý¾Æ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemolytic disease of newborn
    ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemorrhagic disease
    ÃâÇ÷(¼º) Áúȯ.
  • hemorrhagic disease
    ÃâÇ÷¼ºÁúȯ
  • hemorrhagic disease of newborn
    ½Å»ý¾ÆÃâÇ÷(¼º) Áúȯ.
  • hemp disease
    ¸¶¼¶À¯º´.
  • hepatolenticular disease
    °£·»ÁîÇÙÁúȯ.
  • hepatolienal disease
    °£ºñÁúȯ.
  • hereditary disease
    À¯Àüº´.
  • hereditary hemorhagic telangiectasia(osler-weber-rendu disease,)
    À¯Àü¼ºÃâÇ÷¼º¸ð¼¼Ç÷°ü È®Àå
  • heredoconstitutional disease
    À¯ÀüüÁúº´.
  • heredodegenerative disease
    À¯Àüº¯¼º Áúȯ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • foot-and-mouth disease
    ±¸Á¦¿ª (Ï¢ð´æ¹)
  • frozen shoulder =Duplay s disease
    µ¿°á°ß, µ¿°ß°üÀý, À¯Âø¼º °ß °üÀý¸·¿°,¿À½Ê ¾î±ú, µ¿Å뼺 °ß±¸Ãà(Áõ)(ÔÙ÷Ôàõ̷Ϭõêñø), µàÇ÷¹À̺´ .
  • functional cardiovascular disease
    ±â´É¼º ½ÉÇ÷°üº´.
  • fungal disease
    Áø±Õº´(òØÐ¶Ü»).
  • fungal disease
    Áø±ÕÁúȯ(¡­òðü´)
  • fungal disease,deep
    ½ÉºÎ
  • fungal disease,encephalitic
    ³ú¿°¼º(Òàæúàõ)
  • fungal disease,superficial
    Ç¥À缺(øúî¤àõ)
  • fungous disease
    Áø±ÕÁúȯ, °õÆÎÀÌÆò
  • gamma heavy chain disease
    °¨¸¶Á߼⺴(¡­ñìáðÜ»).
  • gamma heavy chain disease
    °¨¸¶Á߼⺴
  • gamma heavy chain disease
    °¨¸¶Á߼⺴(¡­ñìáðÜ»).
  • gamma-chain disease
    °¨¸¶¼âº´, Gamma-chain º´
  • gastric vertigo =trousseau disease
    À§(¼º)Çö±â
  • gastroesophageal reflux disease
    À§½Äµµ¿ª·ùÁúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
DMARDs Disease Modifying Anti-Rheumatic Drugs
ESRD End Stage Renal Disease
FCPD Fibro-Calculous Pancreatic Disease
GERD Gastro-Esophageal Reflux Disease
GTD Gestational Trophoblastic Disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
DMARD Disease Modifying Antirheumatic Drugs
DFS Disease free
DFI Disease free interval
DFS Disease free survival
DSS Disease specific survival
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
von Economo's disease A unique encephalitis, presumably viral in origin, which followed the influenza pandemic of 1914-1918. Symptoms included ophthalmoplegia and marked somnolence, and in many survivors, the delayed development of Parkinson's disease; the basis for postencephalitic Parkinsonism.
Synonym: encephalitis lethargica, polioencephalitis infectiva.
(05 Mar 2000)
Von Gierke's disease <disease> A congenital disease caused by a metabolic error in which the body deposits an abnormally high amount of glycogen in the kidneys and liver, the disease produces symptoms such as hypoglycaemia (low blood sugar) and hyperlipaemia (an excess of lipid molecules in the blood, which can lead to problems such as clogged arteries and heart attacks).
(09 Oct 1997)
von hippel-lindau disease <disease> A congenital disease characterised by the development of blood vesse ltumours in the retina of the eye and in the brain, lesions and cysts canalso develop in the spina lcord, pancreas, kidneys, and other organs.
(09 Oct 1997)
pelvic imflammatory disease <disease> The inflammation of any of the female pelvic organs, usually due to infection from a sexually transmitted disease. PID can result in sterility if left untreated.
(09 Oct 1997)
pelvic inflammatory disease <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections.
(27 Sep 1997)
von Meyenburg's disease A degenerative disease of cartilage producing a bizarre form of arthritis, with collapse of the ears, the cartilaginous portion of the nose, and the tracheobronchial tree; death may occur from chronic infection or suffocation because of loss of stability in the tracheobronchial tree of autosomal origin.
Synonym: chronic atrophic polychondritis, generalised chondromalacia, Meyenburg's disease, Meyenburg-Altherr-Uehlinger syndrome, relapsing perichondritis, systemic chondromalacia, von Meyenburg's disease.
(05 Mar 2000)
von Recklinghausen disease type 1 neurofibromatosis
von Recklinghausen's disease <disease> A rare genetic disorder which affects the cell growth of nerve tissue. Individuals have multiple cutaneous and subcutaneous tumours which appear in late childhood.
Clinical features include medium-brown, flat discolourations to the skin, known as cafe-au-lait spots.
Secondary hypertension may develop from renal artery stenosis, pheochromocytoma or coarctation of the aorta.
Inheritance: autosomal dominant.
(04 Nov 1997)
Von Willebrand disease <disease, haematology> A hereditary platelet disorder caused by defective or deficient Von Willebrand factor, a protein involved in normal blood clotting, that reduces adhesion to collagen but not aggregation. Both bleeding time and coagulation are increased. Factor VIII levels are secondarily reduced.
Symptoms include nosebleeds, bleeding gums, heavy menstrual bleeding, bruising and skin rashes.
Inheritance: autosomal dominant.
(30 Sep 1997)
Von Willebrand's disease <disease> This congenital disease, which is caused a deficiency of a blood factor that promotes platelet adhesion, is characterised by prolonged bleeding and poor blood coagulation.
(09 Oct 1997)
Voorhoeve's disease Linear striations seen radiographically in the metaphyses of long bones and also flat bones; it may be a variant of osteopoikilosis.
Synonym: Voorhoeve's disease.
(05 Mar 2000)
Meige's disease Autosomal dominant lymphedema with onset at about the age of puberty.
(05 Mar 2000)
cerebrovascular disease <cardiology, pathology> A general term which encompasses a variety of diseases which affect (via the occlusive effects of atherosclerosis) the arteries which supply the brain.
See: stroke.
(12 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á